Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Fibrotic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GPR84 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPR84 Recombinant Protein / Fragment High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GPR84 Products |
| Gene Delivery | GPR84 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional assays. |
View GPR84 Products |
| Benchmark Ab | Anti-GPR84 Benchmark Antibody Recombinant positive control for binding and flow cytometry. |
View GPR84 Products |
| Validator | GPR84 siRNA Set For target knockdown validation in primary cells. |
View GPR84 Products |
| Related Target A | FPR2 Synergistic GPCR in resolving inflammation and neutrophil migration. |
View FPR2 Products |
| Related Target B | GPR120 Medium-to-long chain fatty acid receptor involved in metabolic-inflammatory crosstalk. |
View GPR120 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Loss of GPCR Multi-pass Membrane Structure | High-titer Lentivirus Premade Particles for stable cell line generation, enabling native cell-based functional assays. |
| Subfamily Off-target Screening (GPR40/GPR120 cross-reactivity) | Homolog Lentivirus and Target panels strictly sequence-verified for counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live GPR84 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPR84 therapeutics is intensifying, with major players shifting focus from traditional small molecules to highly selective antagonists targeting inflammatory pathways. As first-generation therapies reach the clinic for indications like Idiopathic Pulmonary Fibrosis (IPF) and Inflammatory Bowel Disease (IBD), the next wave of R&D is targeting tissue-specific, peripheral-restricted GPR84 modulation to minimize central nervous system side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Galapagos, Liminal BioSciences | IPF, NASH, IBD | Functional Screening (Need Lentivirus for Stable Cell Line Calcium Flux/cAMP assays) |
| Monoclonal Antibody | Academic / Biotech Consortia | Autoimmune, Neuroinflammation | Conformational Binding (Need Sequence Verified GPR84 overexpressing cells) |
| Combination Therapy | Preclinical consortia | Chronic Kidney Disease (CKD) | Pathway Validation (Need GPR84 siRNA alongside FPR2/GPR120 reagents) |